Filtered By:
Drug: Coumadin

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 3661 results found since Jan 2013.

Potential new uses of non-vitamin K antagonist oral anticoagulants to treat and prevent stroke
Conclusion: There may be a role for NOACs in stroke prevention and treatment beyond atrial fibrillation. Randomized controlled trials are needed to compare NOACs to current stroke prevention and treatment strategies in certain subgroups of patients with cerebrovascular disease.
Source: Neurology - September 21, 2015 Category: Neurology Authors: Yaghi, S., Kamel, H., Elkind, M. S. V. Tags: Stroke prevention, All Cerebrovascular disease/Stroke, Infarction, Cerebral venous thrombosis VIEWS & amp;amp; REVIEWS Source Type: research

Effectiveness and Safety of Apixaban and Rivaroxaban Versus Warfarin for the Secondary Prevention of Stroke or Systemic Embolism Among Nonvalvular Atrial Fibrillation Patients (S51.001)
Conclusions:Among NVAF patients with a prior history of SSE, rivaroxaban reduced ischemic stroke and ICH risk versus warfarin and did not significantly impact major bleeding. Apixaban did not significantly alter patients’ risk of SSE or major bleeding compared to warfarin in this high-risk population.Study Supported by: Bayer Pharma AGDisclosure: Dr. Coleman has received personal compensation for activities with Janssen Scientific affairs, LLC, Bayer Pharma AG, and BIPI . Dr. Coleman has received research support from Janssen Scientific Affairs, LLC, and Bayer Pharma AG. Dr. Bunz has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Coleman, C., Bunz, T. Tags: Cerebrovascular Disease and Interventional Neurology: Stroke Prevention and Translation Source Type: research

Tissue Plasminogen Activator Thrombolytic Therapy for Acute Ischemic Stroke in 4 Hospital Groups in Japan
In October 2005 in Japan, the recombinant tissue plasminogen activator (tPA) alteplase was approved for patients with acute ischemic stroke within 3 hours of onset at a dose of 0.6 mg/kg. The present study was undertaken to assess the safety and efficacy of alteplase in Japan. Between October 2005 and December 2009, a total of 114 consecutive patients admitted to 4 hospitals received intravenous tPA within 3 hours of stroke onset. Clinical backgrounds and outcomes were investigated. The patients were divided into 2 chronological groups: an early group, comprising 45 patients treated between October 2005 and December 2007,...
Source: Journal of Stroke and Cerebrovascular Diseases - October 4, 2011 Category: Neurology Authors: Syoichiro Kono, Kentaro Deguchi, Nobutoshi Morimoto, Tomoko Kurata, Shoko Deguchi, Tohru Yamashita, Yoshio Ikeda, Tohru Matsuura, Hisashi Narai, Nobuhiko Omori, Yasuhiro Manabe, Taijyun Yunoki, Yoshiki Takao, Sanami Kawata, Kenichi Kashihara, Koji Abe Tags: Original Articles Source Type: research

Novel oral anticoagulants: A focused review for stroke physicians
Novel oral anticoagulants provide an effective and convenient alternative to warfarin for stroke prevention in patients with atrial fibrillation. However, novel anticoagulants also present new challenges for stroke physicians, such as measurement of anticoagulant effect in emergency situations, use of thrombolysis in acute ischemic stroke, optimal timing of introduction of novel anticoagulants following acute ischemic stroke, and management of intracerebral hemorrhage. In this review, we propose pragmatic approaches to dealing with challenging management issues that will face stroke physicians who care for patients with ac...
Source: International Journal of Stroke - October 22, 2013 Category: Neurology Authors: Emer R. McGrath, John W. Eikelboom, Moira K. Kapral, Martin J. O'Donnell Tags: Review Source Type: research

Eligibility and Preference of New Oral Anticoagulants in Patients With Atrial Fibrillation: Comparison Between Patients With Versus Without Stroke Clinical Sciences
Conclusions— Patients enrolled in RCTs are partly representative of patients with AF in clinical practice. When time in therapeutic range and bleeding tendency with warfarin use were considered, the use of new oral anticoagulants was preferred in patients with stroke than in nonstroke patients, but they were more likely to be excluded in RCTs.
Source: Stroke - September 22, 2014 Category: Neurology Authors: Yoon, C. H., Park, Y. K., Kim, S. J., Lee, M.-j., Ryoo, S., Kim, G.-M., Chung, C.-S., Lee, K. H., Kim, J. S., Bang, O. Y. Tags: Other anticoagulants Clinical Sciences Source Type: research

Rates of Ischemic Stroke During Warfarin Treatment for Atrial Fibrillation Brief Reports
Conclusions— In a large cohort of older patients with atrial fibrillation, we observed the highest rate of ischemic stroke in the first 30 days after warfarin initiation. Although causation cannot be established given the observational nature of this study, our findings highlight the need for future research in this population.
Source: Stroke - March 23, 2015 Category: Neurology Authors: Tung, J. M., Mamdani, M. M., Juurlink, D. N., Paterson, J. M., Kapral, M. K., Gomes, T. Tags: Cardiovascular Pharmacology, Anticoagulants, Epidemiology Brief Reports Source Type: research

The Speed and Reliability of Pre-Hospital Point-of-Care Laboratory Testing on the Mobile Stroke Treatment Unit (P4.314)
Conclusion: Critical laboratory tests can be performed rapidly and successfully in a MSTU to assist in early pre-hospital ischemic stroke thrombolysis or warfarin reversal in ICH.Disclosure: Dr. Organek has nothing to disclose. Dr. Taqui has nothing to disclose. Dr. Cerejo has nothing to disclose. Dr. Itrat has nothing to disclose. Dr. Buletko has nothing to disclose. Dr. Cho has nothing to disclose. Dr. Sheikhi has nothing to disclose. Dr. Winners has nothing to disclose. Dr. Rasmussen has nothing to disclose. Dr. Hussain has nothing to disclose. Dr. Uchino has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Organek, N., Taqui, A., Cerejo, R., Itrat, A., Buletko, A., Cho, S., Sheikhi, L., Winners, S., Rasmussen, P., Hussain, M., Uchino, K. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke, Prehospital, and Telemedicine Source Type: research

Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack Original Articles
Conclusions— NOACs have had modest but growing uptake over time among atrial fibrillation patients hospitalized with stroke or transient ischemic attack and are prescribed to patients with lower stroke risk compared with warfarin.
Source: Circulation: Cardiovascular Quality and Outcomes - July 21, 2015 Category: Cardiology Authors: Patel, P. A., Zhao, X., Fonarow, G. C., Lytle, B. L., Smith, E. E., Xian, Y., Bhatt, D. L., Peterson, E. D., Schwamm, L. H., Hernandez, A. F. Tags: Other anticoagulants, Embolic stroke, Anticoagulants Original Articles Source Type: research

A rare cause of stroke in young: PHACE syndrome (P1.253)
Conclusions:Neurocutaneous syndromes are typically diagnosed in childhood and can be a rare cause of stroke in young. Our patient suffered an ischemic stroke secondary to sequelae of undiagnosed PHACE syndrome. Early identification of neurocutaneous syndromes allows for proper surveillance, evaluation, and preventative education for development of complications.Disclosure: Dr. Fitzgerald has nothing to disclose. Dr. Chandra has nothing to disclose. Dr. Dannenbaum has nothing to disclose. Dr. Sharrief has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Fitzgerald, K., Chandra, S., Dannenbaum, M., Sharrief, A. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research

Another possible determinant for ischemic stroke with nonvalvular atrial fibrillation other than conventional oral anticoagulant treatment: The relationship between whole blood viscosity and stroke ☆
Prevention of ischemic stroke complication of atrial fibrillation (AF) is the crucial target in the disease. Stroke is largely prevented by warfarin and the introduction of new oral anticoagulants. While warfarin reduces stroke by 60 –70%, new oral anticoagulants provide at least equal success to this reduction with appropriate dose and treatment compliance.1,2 Nonetheless, we still encounter thromboembolic ischemic stroke in clinical practice in AF patients taking oral anticoagulants (OAC) and once experienced, stroke can hav e devastating consequences for the patients.
Source: Journal of Stroke and Cerebrovascular Diseases - August 3, 2022 Category: Neurology Authors: Sezen Baglan Uzunget, Kader Eliz Sahin Source Type: research

90 Day Outcomes in Stroke/Transient Ischemic Attack Patients Receiving Initial or Follow-up Care in a Comprehensive Outpatient Stroke Center (P3.120)
CONCLUSIONS: The completion of diagnostic evaluation and implementation or adjustment of treatments including optimizing antiplatelet therapy or changing to coumadin when cardiac monitoring demonstrates atrial fibrillation in a timely manner has resulted in better than expected outcomes. We feel this is due to "closing the loop" in the episode of care.Disclosure: Dr. Bates has nothing to disclose. Dr. Westphal has nothing to disclose. Dr. Rainka has nothing to disclose. Dr. Gengo has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Bates, V., Westphal, E., Rainka, M., Gengo, F. Tags: Cerebrovascular Disease and Interventional Neurology: Primary and Comprehensive Stroke Centers Source Type: research

Rationale and design of Triple AXEL: trial for early anticoagulation in acute ischemic stroke patients with nonvalvular atrial fibrillation
DiscussionThe results of this proof‐of‐concept trial will guide go/no‐go decision to a large phase 3 confirmatory trial.
Source: International Journal of Stroke - October 26, 2014 Category: Neurology Authors: Keun‐Sik Hong, Yun Jung Choi, Sun U. Kwon, Tags: Protocols Source Type: research

Temporary Discontinuation Of Warfarin For Endovascular Procedures And Risk Of Ischemic Stroke (P4.301)
Conclusions: The risk of ischemic stroke during discontinuation of warfarin is higher than expected and requires a careful evaluation of risk and benefits.Disclosure: Dr. Malik has nothing to disclose. Dr. Qureshi has nothing to disclose. Dr. Zeb has nothing to disclose. Dr. Defillo has nothing to disclose. Dr. Thompson has nothing to disclose. Dr. Suri has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Malik, A., Qureshi, M., Zeb, H., Defillo, A., Thompson, M., Suri, M., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Interventional Treatment for Ischemic Stroke Source Type: research

Antiphospholipid Syndrome of Late Onset: A Difficult Diagnosis of a Recurrent Embolic Stroke
A 77-year-old woman with atrial fibrillation (AF) treated with warfarin had a cortical left middle cerebral artery (MCA) stroke (October 2009, international normalized ratio [INR], 1.6) and a cortical left frontal stroke (October 2011, INR, 1.9). Anticoagulation was adjusted. In October 2011, she had a right frontal stroke (INR, 2.3). Acetylsalicylic acid (ASA) was temporally added to the treatment. In June 2013, she had a left occipital stroke (INR, 2.3). Warfarin was changed to rivaroxaban. In August 2013, she had a right occipital stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - May 12, 2015 Category: Neurology Authors: Montserrat G. Delgado, Sergio Rodríguez, Raquel García, Pablo Sánchez, Antonio Sáiz, Sergio Calleja Tags: Case Report Source Type: research

Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation Clinical Sciences
Conclusions—In this systematic review and meta-analysis, rivaroxaban was as effective as dabigatran, but was more effective than warfarin for the prevention of stroke/thromboembolism in atrial fibrillation patients. Major bleeding risk was significantly higher with rivaroxaban than with dabigatran, as was all-cause mortality and gastrointestinal bleeding. Rivaroxaban was comparable to warfarin for major bleeding, with an increased risk in gastrointestinal bleeding and decreased risk of intracranial hemorrhage.
Source: Stroke - March 27, 2017 Category: Neurology Authors: Ying Bai, Hai Deng, Alena Shantsila, Gregory Y.H. Lip Tags: Meta Analysis, Quality and Outcomes Original Contributions Source Type: research